A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.

James J HardingMelinda TelliPamela MunsterMartin H VossJeffrey R InfanteAngela DeMicheleMark DunphyMai H LeChris MolineauxKeith OrfordFrank ParlatiSam H WhitingMark K BennettNizar M TannirFunda Meric-Bernstam

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Telaglenastat is safe, with a favorable PK/PD profile and signal of antitumor activity, supporting further clinical development.

Keyphrases

squamous cell carcinoma
small cell lung cancer
randomized controlled trial
open label
clinical trial
double blind